Zika virus (ZIKV), Dengue virus (DENV) and yellow fever virus (YFV) are closely related mosquito-borne flaviviruses for which effective treatment or prophylactic options are still scarce.

By isolating a single clone from human isolates, researchers from the National Taiwan University College of Medicine aimed to enhance the immunogenicity of the Zika virus (ZIKV).

The U.S. Department of Health and Human Services (HHS) has released a sweeping plan that is designed to help manage vector-borne pathogens, such as the Zika virus, with the ultimate goal of reducing the related disease burden to zero.

While the biopharma industry was widely praised for its fast response to the COVID-19 pandemic, moves are afoot to ensure that the world is better prepared in case another pandemic hits. Moderna Inc. was one of the companies that blazed a trail in the early stages of the pandemic with its revolutionary mRNA vaccine. Now the firm is investing in manufacturing and R&D in the U.K. to make good on a pledge to respond to the next global disease threat within 100 days of its detection.

A Chinese study led by scientists at Nanjing University is the first to show that modified small extracellular vesicles can cross the placenta and blood-brain barrier to target drug delivery in mice infected with the Zika virus, in which they were shown to significantly reduce fetal neurological damage, including microcephaly.

A multi-omics analysis led by Chinese scientists at Tsinghua University in Beijing has demonstrated that aberrant metabolism of the co-enzyme nicotinamide adenine dinucleotide (NAD+) was responsible for microcephaly induced by Zika virus infection during pregnancy.

A study led by Australian researchers at the University of Queensland has shown that a newly developed antibody targets the flavivirus nonstructural protein 1 and was shown to reduce viremia and improve survival in mouse models of dengue, Zika and West Nile infections.